Table 1.

Intestinal microbial viable counts and percentage distribution of microorganisms from the FMA in CFS patients at the start and end of the trial.

	Baseline (N=22)	End of trial (N=21)
Median (IQR)	Median (IQR)
Streptococcus count	9.83+E06 (2.3+E06–3.1+E07)	6.87E+06 (2.6E+05–4.7E+07)
Enterococcus count	0.00 (0.00–2.3E+06)	0.00 (0.00–7.7E+04)
Lactobacillus count	7.05E+05 (0.00–3.33E+08)	5.00E+05 (0.00–7.0E+05)
Bifidobacterium count⁎	5.5E+07 (5.0E+05–1.7E+09)	5.00E+05 (0.00–5.0E+07)
Streptococcus %⁎	72.36 (44.8–93.59)	39.54 (1.77–96.78)
Enterococcus %	0.00 (0.00–13.03)	0.00 (0.00–0.19)
Lactobacillus %	0.00 (0.00–0.22)	0.00 (0.00–0.01)
Bifidobacterium %⁎	0.24 (0.00–10.19)	0.00 (0.00–0.00)

^⁎Wilcoxon test results p<0.05.